Duloxetine Capsule, Delayed Release
Product Images NDC 42708-196

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 42708-196). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qpharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (42708 196 30 Label)

This text provides dosage instructions for Duloxetine Delayed-Release Capsules USP, 60mg, which recommends taking one capsule a certain number of times daily for a specified number of days. It also mentions storing the medication in controlled conditions.*

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

FDA Label Image

Structure (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 01)

FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 02)

This text provides data on the proportion of patients with relapse over time for a placebo group and a group treated with duloxetine. The information is presented in a graph showing the time from randomization to relapse in days. The Kaplan-Meier estimator method was likely used to analyze the data.*

FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 03)

This text provides information on the proportion of patients experiencing a relapse over time while being treated with either a placebo or Duloxetine. The data shows the number of patients at risk at different time points and the treatment they were receiving. The Kaplan-Meier estimator method was likely used to determine these statistics.*

FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 04)

This text provides information on the percentage of patients improved with different dosages of Duloxetine and Placebo. It also mentions the percent improvement in pain from baseline. This data can be valuable for evaluating the effectiveness of these treatments in managing pain.*

FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 05)

FDA Label Image

Fig 5 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 06)

This description provides information on the percentage of patients improved with different levels of pain improvement from baseline while taking Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and Placebo. The data is presented in a comparison chart for easy interpretation.*

FDA Label Image

Fig 6 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 07)

This text provides data on the percentage of patients improved with different doses of Duloxetine and placebo. The chart indicates the level of pain improvement from baseline based on the treatment received. It shows that Duloxetine at varying doses, including 120 mg twice daily and 60 mg once daily, resulted in noticeable improvements compared to the placebo group. The percentage of improvement is provided for different milestones from 0 to 100.*

FDA Label Image

Fig 7 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 08)

The text describes the results of a study (Study FM-4) on pediatric patients aged 13 to 17 years with Juvenile Fibromyalgia Syndrome. The study compared the percentage of patients achieving different levels of pain relief at week 12 when treated with Duloxetine 60mg Once Daily versus a Placebo. The pain relief was measured using the Brief Pain Inventory - Modified Short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30mg once daily for 1 week and were titrated to 60mg once daily for 12 weeks.*

FDA Label Image

Figure 8 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 09)

Percentage of Patients Improved: This data table shows the percentage of patients who experienced improvement in pain levels from baseline in a clinical trial comparing a placebo group to those taking Duloxetine 60/120 mg once daily. The chart also displays the percent improvement in pain from baseline through various time points during the study.*

FDA Label Image

Figure 9 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 10)

This text provides information about the percentage of patients improved with Duloxetine 60 mg compared to a placebo. It shows a graph with percentage improvement in pain from baseline (BOCF) ranging from 50% to 100% based on the treatment received.*

FDA Label Image

Figure 10 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 11)

The text provides information on the percentage of patients who showed improvement in pain levels when treated with placebo and Duloxetine 60/120 mg once daily. It indicates that 100% of patients improved with Duloxetine compared to the placebo. Additionally, the text mentions a scale showing different increments of percentage improvement in pain from baseline.*

FDA Label Image

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.